NOVARTIS SAUDI

Novartis Saudi Arabia Company Introduction

Novartis Saudi Arabia is the local subsidiary of Novartis AG, a leading global healthcare company based in Switzerland. The company is dedicated to reimagining medicine to improve and extend people's lives. In Saudi Arabia, Novartis focuses on bringing innovative medicines to patients across various therapeutic areas, including oncology, cardiovascular, immunology, neuroscience, and ophthalmology. Novartis Saudi Arabia is committed to advancing healthcare in the Kingdom through its portfolio of pharmaceutical products, medical research, and patient access initiatives, striving to address unmet medical needs and contribute to the health and well-being of the Saudi population.

Factory or Trader:

Novartis Saudi Arabia primarily operates as a trader. It functions as a commercial entity responsible for the sales, marketing, and distribution of pharmaceutical products manufactured by its global parent company and its international manufacturing network. It is not primarily a manufacturing plant (factory) for active pharmaceutical ingredients or the final drug products themselves within Saudi Arabia.

Novartis Saudi Arabia manufactures or sells products primarily in the following therapeutic areas and includes products such as:

Oncology

Kisqali

Scemblix

Pluvicto

Cardiovascular Renal and Metabolism

Entresto

Leqvio

Immunology Hepatology and Dermatology

Cosentyx

Neuroscience

Gilenya

Mayzent

Ophthalmology

Lucentis

Beovu

Respiratory

Xolair

Established Medicines

Voltaren Diclofenac

Diovan Valsartan